Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus

Journal of Clinical Immunology

Volumn 30, Issue 1, 2010, Pages 106-113

  Pranzatelli, Michael R ^a   Tate, Elizabeth D ^a   Travelstead, Anna L ^a   Colliver, Jerry A ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti B cell therapy; B cell recovery; Memory B cells; Neuroblastoma; Paraneoplastic syndrome

Indexed keywords

ACTHAR GEL; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CORTICOTROPIN[1-39]; IMMUNOGLOBULIN; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MONOTHERAPY; MULTICENTER STUDY; NATURAL KILLER CELL; OPSOCLONUS MYOCLONUS SYNDROME; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INFANT; LYMPHOCYTE SUBSETS; MALE; OPSOCLONUS-MYOCLONUS SYNDROME; T-LYMPHOCYTES; TIME FACTORS;

EID: 77249095007     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-009-9335-3     Document Type: Article

References (27)

1. J-P Stüben 2008 B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders J Neuroimmunol. 204 1 12 10.1016/j.jneuroim. 2008.07.019
2. NL Monson PD Cravens EM Frohman K Hawker MK Racke 2005 Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis Arch Neurol. 62 258 264 10.1001/archneur.62.2.258 15710854 (Pubitemid 40204747)
3. AH Cross JL Stark J Lauber MJ Ramsbottom J Lyons 2006 Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients J Neuroimmunol. 180 63 70 10.1016/j.jneuroim.2006.06.029 1:CAS:528: DC%2BD28Xht1SmsL3N 16904756 (Pubitemid 44767709)
4. A Pestronk J Florence T Miller R Choksi MT Al-Lozi TD Levine 2003 Treatment of IgM antibody associated polyneuropathies using rituximab J Neurol Neurosurg Psychiatry. 74 485 489 10.1136/jnnp.74.4.485 1:STN:280: DC%2BD3s7is1Sjtg%3D%3D 12640069 (Pubitemid 36379372)
5. JH Anolik JW Friedberg B Zheng J Barnard T Owen E Cushing, et al. 2007 B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny Clin Immunol. 122 139 145 10.1016/j.clim.2006.08.009 1:CAS:528:DC%2BD2sXltFWhuw%3D%3D 17008130 (Pubitemid 46073890)
6. JO Pers C Daridon B Bendaoud V Devauchelle C Berthou A Saraux, et al. 2008 B-cell depletion and repopulation in autoimmune diseases Clin Rev Allergy Immunol. 34 50 55 10.1007/s12016-007-8015-4 1:CAS:528:DC%2BD1cXkt1KmtbY%3D 18270858
7. M Tokunaga K Saito D Kawabata Y Imura T Fujii S Nakayamada, et al. 2007 Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis. 66 470 475 10.1136/ard.2006.057885 1:CAS:528:DC%2BD2sXkvFeks7w%3D 17107983 (Pubitemid 46580466)
8. ED Tate TJ Allison MR Pranzatelli SJ Verhulst 2005 Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome J Pediatr Oncol Nurs. 22 8 19 10.1177/1043454204272560 15574722 (Pubitemid 40091116)
9. ED Tate MR Pranzatelli JA Harber AL Travelstead SJ Verhulst GA Fenton JP Frazer TJ Geller WD Graf HM Kelfer KD Mathews GP Raju P Raman 2007 Pharmacokinetic and time-course study of rituximab in pediatric opsoclonus-myoclonus syndrome Ann Neurol. 62 suppl 11 S113
10. MR Pranzatelli ED Tate AL Travelstead D Longee 2005 Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus Pediatrics. 115 e115 e119 15601813
11. MR Pranzatelli AL Travelstead ED Tate TJ Allison SJ Verhulst 2004 CSF B cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity Mov Disord. 19 770 777 10.1002/mds.20125 15254934 (Pubitemid 39139587)
12. MR Pranzatelli ED Tate AL Travelstead J Barbosa RA Bergamini L Civitello, et al. 2006 Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome J Pediatr Hematol/Oncol. 28 585 593 10.1097/01.mph.0000212991.64435.f0 1:CAS:528:DC%2BD28XhtFKqtrvO (Pubitemid 44496336)
13. MR Pranzatelli AL Travelstead ED Tate TJ Allison EJ Moticka DN Franz, et al. 2004 B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes Neurology. 62 1526 1532 1:STN:280:DC%2BD2c3jvVynuw%3D%3D 15136676
14. MR Pranzatelli 1996 The immunopharmacology of the opsoclonus-myoclonus syndrome Clin Neuropharmacol. 19 1 47 10.1097/00002826-199619010-00001 1:CAS:528:DyaK28Xhs1Sjt7s%3D 8867515
15. WM Comans-Bitter R De Groot R van den Beemd HJ Neijens WC Hop K Groeneveld, et al. 1997 Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations J Pediatr. 130 388 393 10.1016/S0022-3476(97)70200-2 1:STN:280:DyaK2s3hsleqsA%3D%3D 9063413 (Pubitemid 27492682)
16. I Sanz JH Anolik RJ Looney 2007 B cell depletion therapy in autoimmune diseases Front Biosci. 12 2546 2567 10.2741/2254 1:CAS:528:DC%2BD28Xht1OnsbnP 17127262
17. HF Petereit W Moeller-Hartmann D Reske A Rubbert 2008 Rituximab in a patient with multiple sclerosis-effect on B cells, plasma cells and intrathecal IgG synthesis Acta Neurol Scand. 117 399 403 10.1111/j.1600-0404.2007.00958.x 1:STN:280:DC%2BD1c3ps12gtA%3D%3D 18031564 (Pubitemid 351643667)
18. O Stüve S Cepok B Elias A Saleh HP Hartung B Hemmer, et al. 2005 Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis Arch Neurol. 62 1620 1623 10.1001/archneur.62.10.1620 16216948 (Pubitemid 41434570)
19. RA Sidner BK Book A Agarwal CM Bearden CA Vieira MD Pescovitz 2004 In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody Hum Antib. 13 55 62 1:CAS:528: DC%2BD2cXhtVahsLnI
20. T Vallerskog I Gunnarsson M Widhe A Risselada L Klareskog R van Vollenhoven, et al. 2007 Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE Clin Immunol. 122 62 74 10.1016/j.clim.2006.08.016 1:CAS:528:DC%2BD28Xhtlalt7bE 17046329 (Pubitemid 46026695)
21. NL Bernasconi N Onai A Lanzavecchia 2003 A role for Toll-like receptors in acquired immunity. Upregulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells Blood. 101 4500 4504 10.1182/blood-2002-11-3569 1:CAS:528:DC%2BD3sXktFKhurc%3D 12560217 (Pubitemid 36857820)
22. RJ Looney JH Anolik D Campbell RE Felgar F Young LJ Arend, et al. 2004 B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum. 50 2580 2589 10.1002/art.20430 1:CAS:528:DC%2BD2cXnsVKht7s%3D 15334472 (Pubitemid 39062719)
23. P Roll A Palanichamy C Kneitz T Dorner HP Tony 2006 Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis Arthritis Rheum. 54 2377 2386 10.1002/art.22019 1:CAS:528:DC%2BD28XpsFGgu7k%3D 16869000 (Pubitemid 44204997)
24. H Genberg A Hansson A Wernerson L Wennberg G Tydén 2006 Pharmacodynamics of rituximab in kidney allotransplantation Am J Transplant. 6 2418 2428 10.1111/j.1600-6143.2006.01497.x 1:CAS:528:DC%2BD28XhtFGqsrbK 16925569 (Pubitemid 44359429)
25. MJ Leandro G Cambridge MR Ehrenstein JC Edwards 2006 Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis Rheum. 54 613 620 10.1002/art.21617 1:CAS:528:DC%2BD28XhvFKhsbg%3D 16447239 (Pubitemid 43228639)
26. R Stasi G Del Poeta E Stipa ML Evangelista MM Trawinska N Cooper, et al. 2007 Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura Blood 110 2924 2930 10.1182/blood-2007-02-068999 1:CAS:528: DC%2BD2sXht1Smu77J 17548576 (Pubitemid 350006946)
27. A Agarwal CA Vieira BK Book RA Sidner NS Fineberg MD Pescovitz 2004 Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T cell responses Am J Transplant. 4 1357 1360 10.1111/j.1600-6143.2004. 00502.x 1:CAS:528:DC%2BD2cXntVaht7s%3D 15268740 (Pubitemid 39013585)